BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 37210683)

  • 1. Long-Term Postsurgical Outcomes of Neoadjuvant Chemoradiation (CROSS) Versus Chemotherapy (FLOT) for Multimodal Treatment of Adenocarcinoma of the Esophagus and the Esophagogastric Junction.
    Gebauer F; Plum PS; Damanakis A; Chon SH; Popp F; Zander T; Quaas A; Fuchs H; Schmidt T; Schröder W; Bruns CJ
    Ann Surg Oncol; 2023 Nov; 30(12):7422-7433. PubMed ID: 37210683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-term outcome of Ivor Lewis esophagectomy following neoadjuvant chemoradiation versus perioperative chemotherapy in patients with locally advanced adenocarcinoma of the esophagus and gastroesophageal junction: a propensity score-matched analysis.
    Plum PS; Damanakis A; Buschmann L; Ernst A; Datta RR; Schiffmann LM; Zander T; Fuchs H; Chon SH; Alakus H; Schröder W; Hölscher AH; Bruns CJ; Bludau M
    J Cancer Res Clin Oncol; 2022 May; 148(5):1223-1234. PubMed ID: 34223965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAV.
    Lorenzen S; Biederstädt A; Ronellenfitsch U; Reißfelder C; Mönig S; Wenz F; Pauligk C; Walker M; Al-Batran SE; Haller B; Hofheinz RD
    BMC Cancer; 2020 Sep; 20(1):886. PubMed ID: 32933498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postoperative and Pathological Outcomes of CROSS and FLOT as Neoadjuvant Therapy for Esophageal and Junctional Adenocarcinoma: An International Cohort Study From the Oesophagogastric Anastomosis Audit (OGAA).
    Oesophago-Gastric Anastomotic Audit (OGAA) Collaborative
    Ann Surg; 2023 May; 277(5):e1026-e1034. PubMed ID: 35099168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286).
    Hoeppner J; Lordick F; Brunner T; Glatz T; Bronsert P; Röthling N; Schmoor C; Lorenz D; Ell C; Hopt UT; Siewert JR
    BMC Cancer; 2016 Jul; 16():503. PubMed ID: 27435280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Facing adenocarcinoma of distal esophagus and esophagogastric junction: a CROSS versus FLOT propensity score-matched analysis of oncological outcomes in a high-volume institution.
    Lombardi PM; Pansa A; Basato S; Giorgi L; Perano V; Marano S; Castoro C
    Updates Surg; 2023 Jun; 75(4):921-930. PubMed ID: 36991302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant chemotherapy or chemoradiation for patients with advanced adenocarcinoma of the oesophagus? A propensity score-matched study.
    Favi F; Bollschweiler E; Berlth F; Plum P; Hescheler DA; Alakus H; Semrau R; Celik E; Mönig SP; Drebber U; Hölscher AH
    Eur J Surg Oncol; 2017 Aug; 43(8):1572-1580. PubMed ID: 28666624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
    Al-Batran SE; Hofheinz RD; Pauligk C; Kopp HG; Haag GM; Luley KB; Meiler J; Homann N; Lorenzen S; Schmalenberg H; Probst S; Koenigsmann M; Egger M; Prasnikar N; Caca K; Trojan J; Martens UM; Block A; Fischbach W; Mahlberg R; Clemens M; Illerhaus G; Zirlik K; Behringer DM; Schmiegel W; Pohl M; Heike M; Ronellenfitsch U; Schuler M; Bechstein WO; Königsrainer A; Gaiser T; Schirmacher P; Hozaeel W; Reichart A; Goetze TO; Sievert M; Jäger E; Mönig S; Tannapfel A
    Lancet Oncol; 2016 Dec; 17(12):1697-1708. PubMed ID: 27776843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Docetaxel-Based Neoadjuvant Chemotherapy Followed by En Bloc Resection for Esophageal Adenocarcinoma: A 15-Year Retrospective Analysis from a Regional Upper Gastrointestinal Cancer Network.
    Tankel J; Ahmed N; Mueller C; Najmeh S; Spicer J; Mulder D; Cool-Lartigue J; Rousseau M; Frechette D; Sud S; Kavan P; Moghrabi A; Champagne M; Lemay F; Dalfen R; Sirhan S; Asselah J; Alcindor T; Ferri L
    Ann Surg Oncol; 2024 Apr; 31(4):2461-2469. PubMed ID: 38142255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognosis after neoadjuvant chemoradiation or chemotherapy for locally advanced gastro-oesophageal junctional adenocarcinoma.
    Vos EL; Carr RA; Hsu M; Nakauchi M; Nobel T; Russo A; Barbetta A; Tan KS; Tang L; Ilson D; Ku GY; Wu AJ; Janjigian YY; Yoon SS; Bains MS; Jones DR; Coit D; Molena D; Strong VE
    Br J Surg; 2021 Nov; 108(11):1332-1340. PubMed ID: 34476473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perioperative Chemotherapy for Gastro-Esophageal or Gastric Cancer: Anthracyclin Triplets versus FLOT.
    Geerts JFM; van der Zijden CJ; van der Sluis PC; Spaander MCW; Nieuwenhuijzen GAP; Rosman C; van Laarhoven HWM; Verhoeven RHA; Wijnhoven BPL; Lagarde SM; Mostert B
    Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38610969
    [No Abstract]   [Full Text] [Related]  

  • 12. CROSS Versus FLOT Regimens in Esophageal and Esophagogastric Junction Adenocarcinoma: A Propensity-Matched Comparison.
    Donlon NE; Moran B; Kamilli A; Davern M; Sheppard A; King S; Donohoe CL; Lowery M; Cunningham M; Ravi N; Mueller C; Cools-Lartigue J; Ferri L; Reynolds JV
    Ann Surg; 2022 Nov; 276(5):792-798. PubMed ID: 35876385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advanced esophagogastric cancer.
    Lorenzen S; Pauligk C; Homann N; Schmalenberg H; Jäger E; Al-Batran SE
    Br J Cancer; 2013 Feb; 108(3):519-26. PubMed ID: 23322206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR).
    Dos Santos M; Lequesne J; Leconte A; Corbinais S; Parzy A; Guilloit JM; Varatharajah S; Brachet PE; Dorbeau M; Vaur D; Weiswald LB; Poulain L; Le Gallic C; Castera-Tellier M; Galais MP; Clarisse B
    BMC Cancer; 2022 May; 22(1):537. PubMed ID: 35549674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy aNd chemoradiotherapy for adenocarcinoma of the OESophagus and esophagogastric junction with oligometastases: Protocol of the TNT-OES-1 trial.
    van der Zijden CJ; Eyck BM; van der Gaast A; van Doorn L; Nuyttens JJME; van Lanschot JJB; Wijnhoven BPL; Mostert B; Lagarde SM
    Contemp Clin Trials Commun; 2022 Aug; 28():100934. PubMed ID: 35669486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].
    Tian Y; Wang Q; Wang J; Qiao XY; Zhang J; Lin YC; Li Y; Fan LQ; Yang PG; Zhao Q
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):128-137. PubMed ID: 33508918
    [No Abstract]   [Full Text] [Related]  

  • 17. Evaluation of tumor regression by neoadjuvant chemotherapy regimens for esophageal adenocarcinoma: a systematic review and meta-analysis.
    Chidambaram S; Sounderajah V; Maynard N; Owen R; Markar SR
    Dis Esophagus; 2023 Jan; 36(2):. PubMed ID: 36151055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative analysis of long-term oncologic outcomes for minimally invasive and open Ivor Lewis esophagectomy after neoadjuvant chemoradiation: a propensity score matched observational study.
    Merritt RE; Kneuertz PJ; Abdel-Rasoul M; D'Souza DM; Perry KA
    J Cardiothorac Surg; 2021 Dec; 16(1):347. PubMed ID: 34872562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The postoperative part of perioperative chemotherapy fails to provide a survival benefit in completely resected esophagogastric adenocarcinoma.
    Sisic L; Blank S; Nienhüser H; Haag GM; Jäger D; Bruckner T; Ott K; Schmidt T; Ulrich A
    Surg Oncol; 2020 Jun; 33():177-188. PubMed ID: 28684226
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.